Evidence map›Paper›PMID 27058347›Full record

ArticlePLoS pathogens2016

FleA Expression in Aspergillus fumigatus Is Recognized by Fucosylated Structures on Mucins and Macrophages to Prevent Lung Infection.

Sheena C Kerr, Gregory J Fischer, Meenal Sinha, Orla McCabe, Jonathan M Palmer, Tsokyi Choera, Fang Yun Lim, Michaela Wimmerova, Stephen D Carrington, Shaopeng Yuan and 4 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 52 citations in OpenAlex.

  1. Review
  2. Requirement for Fucosyltransferase 2 in Allergic Airway Hyperreactivity and Mucus Obstruction.American journal of respiratory cell and molecular biology · 2025
    Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Journal of fungi (Basel, Switzerland) · 2022
    Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Sensing the threat posed by Aspergillus infection.Current opinion in microbiology · 2020
    Review
  14. Article
  15. Review
  16. Aspergillus fumigatus and Aspergillosis in 2019.Clinical microbiology reviews · 2019
    Review
  17. Review
  18. Review
  19. Review
  20. Mucociliary Defense: Emerging Cellular, Molecular, and Animal Models.Annals of the American Thoracic Society · 2018
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 3 countries.

Sheena C KerrDivision of Pulmonary and Critical Care Medicine, University of California, San Francisco, San Francisco, California.
Gregory J FischerDepartment of Genetics, University of Wisconsin, Madison, Madison, Wisconsin.
Meenal SinhaDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, California.
Orla McCabeCenter for Synthesis and Chemical Biology, University College Dublin, Dublin, Ireland.
Jonathan M PalmerDepartment of Medical Microbiology and Immunology, University of Wisconsin, Madison, Madison, Wisconsin.
Tsokyi ChoeraDepartment of Medical Microbiology and Immunology, University of Wisconsin, Madison, Madison, Wisconsin.
Fang Yun LimDepartment of Medical Microbiology and Immunology, University of Wisconsin, Madison, Madison, Wisconsin.
Michaela WimmerovaFaculty of Science and Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
Stephen D CarringtonVeterinary Science Centre, School of Agriculture, Food Science and Veterinary Medicine, University College Dublin, Dublin, Ireland.
Shaopeng YuanDivision of Pulmonary and Critical Care Medicine, University of California, San Francisco, San Francisco, California.
Clifford A LowellDepartment of Laboratory Medicine, University of California, San Francisco, San Francisco, California.
Stefan OscarsonCenter for Synthesis and Chemical Biology, University College Dublin, Dublin, Ireland.
Nancy P KellerDepartment of Medical Microbiology and Immunology, University of Wisconsin, Madison, Madison, Wisconsin.
John V FahyDivision of Pulmonary and Critical Care Medicine, University of California, San Francisco, San Francisco, California.
University of California, San Francisco · USUniversity of Wisconsin–Madison · USUniversity College Dublin · IECentral European Institute of Technology – Masaryk University · CZ

Funding

PREDOCTORAL TRAINING PROGRAM IN GENETICST32GM007133 · NIGMS · UNIVERSITY OF WISCONSIN-MADISON · PI PERNA, NICOLE T · 1985 to 2023
$16.5M
Pre Clinical and Clinical Development of a Novel Thiol-Saccharide MucolyticP01HL128191 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FAHY, JOHN V · 2016 to 2020
$13.4M
Protein carbohydrate interactions in the pathophysiology of asthma exacerbationsR01HL080414 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI John V Fahy · 2005 to 2026
$9.2M
Clinical and Molecular Phenotypes of Severe AsthmaU10HL109146 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FAHY, JOHN V · 2011 to 2016
$4.0M
Mechanisms of Neutrophil ActivationR01AI065495 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LOWELL, CLIFFORD A · 2005 to 2017
$3.7M
Mechanisms of an Aspergillus fumigatus virulence mutantR01AI065728 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI KELLER, NANCY P · 2006 to 2017
$3.6M
Regulation of Innate Immune Signaling by Lyn KinaseR01AI113272 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LOWELL, CLIFFORD A · 2015 to 2019
$2.0M
Preventing fucose-dependent binding of aspergillus and pseudomonas to lung mucinP50HL107191 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FAHY, JOHN V · 2011 to 2012
$848k
NHLBI NIH HHS HL080414NHLBI NIH HHS HL107191NHLBI NIH HHS HL109146NHLBI NIH HHS P01 HL128191NHLBI NIH HHS P50 HL107191NHLBI NIH HHS R01 HL080414NHLBI NIH HHS U10 HL109146NIAID NIH HHS R01 AI065495NIAID NIH HHS R01 AI065728NIAID NIH HHS R01 AI065728-01NIAID NIH HHS R01 AI113272NIGMS NIH HHS T32 GM007133PHS HHS R01068150
6 · The paper itself

Abstract

The immune mechanisms that recognize inhaled Aspergillus fumigatus conidia to promote their elimination from the lungs are incompletely understood. FleA is a lectin expressed by Aspergillus fumigatus that has twelve binding sites for fucosylated structures that are abundant in the glycan coats of multiple plant and animal proteins. The role of FleA is unknown: it could bind fucose in decomposed plant matter to allow Aspergillus fumigatus to thrive in soil, or it may be a virulence factor that binds fucose in lung glycoproteins to cause Aspergillus fumigatus pneumonia. Our studies show that FleA protein and Aspergillus fumigatus conidia bind avidly to purified lung mucin glycoproteins in a fucose-dependent manner. In addition, FleA binds strongly to macrophage cell surface proteins, and macrophages bind and phagocytose fleA-deficient (∆fleA) conidia much less efficiently than wild type (WT) conidia. Furthermore, a potent fucopyranoside glycomimetic inhibitor of FleA inhibits binding and phagocytosis of WT conidia by macrophages, confirming the specific role of fucose binding in macrophage recognition of WT conidia. Finally, mice infected with ΔfleA conidia had more severe pneumonia and invasive aspergillosis than mice infected with WT conidia. These findings demonstrate that FleA is not a virulence factor for Aspergillus fumigatus. Instead, host recognition of FleA is a critical step in mechanisms of mucin binding, mucociliary clearance, and macrophage killing that prevent Aspergillus fumigatus pneumonia.

Indexed as

AdultAnimalsAspergillus fumigatusBlotting, WesternDisease Models, AnimalFemaleFlow CytometryFluorescent Antibody TechniqueFucoseFungal ProteinsHumansImmunity, MucosalLectinsMacrophagesMaleMiceFucosefucose-binding lectinFungal ProteinsLectinsMucins

Identifiers

PMID27058347
PMCPMC4825926
OpenAlexW2329040846

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.